Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 2/20 | 0.31 |
| ▸ | GABRD | O14764 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.31 |
| ▸ | GABRE | P78334 | 2/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.31 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1451846 | 0.98 | CA1 (0.39) | CA1CPT2CPT1AGABRPGABRD | |
| Acetic Acid SCHEMBL40807 | 0.98 | CA1 (0.39) | CA1CPT2CPT1AGABRPGABRD | |
| Acetic Acid SCHEMBL2012317 | 0.94 | CA1 (0.35) | CA1CPT2CPT1AGABRPGABRD | |
| Acetic Acid SCHEMBL10890984 | 0.94 | CA1 (0.35) | CA1CPT2CPT1AGABRPGABRD | |
| Acetic Acid SCHEMBL2013456 | 0.94 | CA1 (0.35) | CA1CPT2CPT1AGABRPGABRD | |
| Acetic Acid SCHEMBL11535921 | 0.94 | CA1 (0.35) | CA1CPT2CPT1AGABRPGABRD | |
| Acetic Acid SCHEMBL2167990 | 0.85 | GABRR1 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Acetic Acid SCHEMBL10585177 | 0.85 | GABRR1 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Acetic Acid SCHEMBL20387 | 0.85 | GABRR1 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Acetic Acid SCHEMBL7717906 | 0.83 | GABRR1 (0.35) | CA1GABRR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1108712-B1 | 3-Hydroxy-4,5-bis(morpholin-1-yl)pyridazine as UV absorber | SHISEIDO CO LTD (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-6476024-B1 | Pyridazine derivatives and related composition | SHISEIDO CO. LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6395896-B2 | REACTING AT LEAST 10 WT % OF 4,5-DICHLORO-3-HYDROXYPYRIDAZINE OR 4,5-DIBROMO-3-HYDROXYPYRIDAZINE OR A MIXTURE WITH ATLEAST 20 VOL% OF MORPHOLINE IN A REACTION SOLUTION AT 70 DEGREE C. OR HIGHER; ULTRAVIOLET ABSORBENTS AND PHOTOSTABILIZERS | SHISEIDO CO., LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
| US-20010012841-A1 | Pyridazine derivatives, manufacturing method and related composition | SHISEIDO CO., LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| EP-1108712-A1 | 3-Hydroxy-4,5-bis(morpholin-1-yl)pyridazine as UV absorber | SHISEIDO COMPANY LIMITED (JP) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012841-A1 | Pyridazine derivatives, manufacturing method and related composition | CYP4F12, CYP4Z1, CYP3A5 | CA1 4873/4885CPT2 4161/4885CPT1A 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.